Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity

Julia Chudzian 1, Anna Szlachcic 1, Małgorzata Zakrzewska 1, Mirosława Czub 2, Marcin Pustula 2, Tad A. Holak 2 and Jacek Otlewski 1,*

1 Department of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Joliot-Curie 14A, 50-383 Wrocław, Poland; julia.chudzian@uwr.edu.pl (J.C.); anna.szlachcic@uwr.edu.pl (A.S.); małgorzata.zakrzewska@uwr.edu.pl (M.Z.)
2 Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland; miroslawa.luty@gmail.com (M.C.); pustula.marcin@gmail.com (M.P.); holak@chemia.uj.edu.pl (T.A.H.)
* Correspondence: jacek.otlewski@uwr.edu.pl; Tel.: +48-71-375-2824

Received: 23 May 2018; Accepted: 17 August 2018; Published: 21 August 2018

Abstract: Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their ligands can promote tumor growth and angiogenesis in many tumor types, including lung or breast cancer. The development of FGF1-targeting molecules with potential implications for the therapy of FGF1-driven tumors is recently being considered a promising approach in the treatment of cancer. In this study we have used phage display selection to find scFv antibody fragments selectively binding FGF1 and preventing it from binding to its receptor. Three identified scFv clones were expressed and characterized with regard to their binding to FGF1 and ability to interfere with FGF1-induced signaling cascades activation. In the next step the scFvs were cloned to scFv-Fc format, as dimeric Fc fusions prove beneficial in prospective therapeutic application. As expected, scFvs-Fc exhibited significantly increased affinity towards FGF1. We observed strong antiproliferative activity of the scFvs and scFvs-Fc in the in vitro cell models. Presented antibody fragments serve as novel FGF1 inhibitors and can be further utilized as powerful tools to use in the studies on the selective cancer therapy.

Keywords: scFv antibody fragments; scFv-Fc fusions; phage display; FGF1; FGFR; ligand trap; tumor targeting treatment; growth factor receptor targeting

1. Introduction

Deregulated growth factor’s receptors play a fundamental role in the development and progression of a variety of human cancers, and are one of the intensively studied therapeutic targets. We focused on fibroblast growth factor 1 (FGF1) and its receptor (FGFR), a member of receptor tyrosine kinase family (RTKs), as its overexpression or aberrant activation has been reported in breast [1,2], lung [3], and gastric cancers [4]. Moreover, the importance of FGFR-targeted therapy lies also in the interplay and complementarity between different growth factor receptors and their downstream signaling—it has been reported that for EGFR, VEGFR, and FGFR, inhibition of one of them leads to compensation in signaling from the remaining ones [5,6]. Additionally, angiogenic properties of FGFRs may further facilitate cancer progression and tumor growth.

Based on the role of the FGF1–FGFR signaling axis in cancer, a number of novel drugs targeting this pathway have been developed and are recently undergoing preclinical and clinical trials in various FGFR-related tumors [7,8]. Current FGFR activation inhibitors can be divided into three groups: small molecule receptor tyrosine kinase inhibitors (TKIs), antagonistic antibody or peptide inhibitors,
and FGF ligand traps. TKIs suffer from relatively low specificity towards individual growth factor receptors and thus present a risk of increased side-effects when administered clinically [9].

FGFR-targeted antibodies and peptide inhibitors act by binding to the extracellular domain of the receptor and competing for binding with its ligand, a strategy that proved to be effective i.e., in the clinical use of trastuzumab blocking HER2 receptor [10]. Several antibodies targeting different members of FGFR family have been developed [11]. For example, anti-FGFR2 antibodies displayed high efficacy in mice against FGFR-overexpressing breast cancer (GP369 and GAL-FR22) and gastric cancer (GAL-FR21) xenografts [12–14]. MFGR1877S, an anti-FGFR3 antibody, showed very promising results in preclinical studies, but tested in phase I clinical study for urothelial cancers and multiple myeloma yielded equivocal results [15].

The last group of molecules disrupting FGFR signaling are ligand traps that sequester growth factor ligand precluding its binding to the receptor, and thereby inhibiting FGFR activation. Ligand traps are based either on FGF fragments acting as decoy molecules [16,17], peptides derived from natural FGF binders [18,19], or anti-FGF antibodies. Currently known anti-FGF antibodies have been developed mostly against FGF2, either generated in mice [20] or selected by screening libraries of formats such as scFv [21] and later reformatted to diabody [22]. Besides FGF2, mouse antibodies have been generated also against FGFR1, FGFR8b, and FGFR23 and were shown to inhibit growth of breast and prostate cancer cells [23–25].

With fibroblast growth factors and their receptors being increasingly studied and taking into account their role in cancer-directed therapy, in this study we report the development of specific human antibody fragments, targeting fibroblast growth factor 1, that act as FGF1 ligand traps. The binders in scFv format were selected from the Tomlinson I and J libraries, fully characterized, and reformatted to bivalent scFv-Fc fusions. Their effectiveness was evaluated by detailed binding tests, as well as investigating their ability to inhibit FGF1-induced cell proliferation. Our results indicate that developed scFvs and scFvs-Fc reduce the in vitro proliferation of FGFR1-expressing mouse fibroblast NIH/3T3 cells, FGFR1-transfected BaF3 cells, and most importantly G-292 human osteosarcoma cancer cells.

2. Results

2.1. Selection of Human scFv Antibody Fragments Specific for FGF1

FGF1-specific scFv antibody fragments were selected from the Tomlinson I + J libraries. In addition to the actual selection of scFvs binding FGF1, each round of selection included counterselection with FGF1 mutant characterized by dramatically reduced affinity to FGFR (FGF1 Y94A/N95A) [26]. The use of this protein in the counterselection step enabled significant depletion of phage clones presenting scFv fragments recognizing receptor-binding deficient FGF1 variant and increased the probability that clones selected afterwards against wild-type FGF1 will bind to the region involved in the interaction with the receptor. In the third round of selection additional competitive elution performed with ECD_FGFR1-Fc was used to obtain a pool of phages presenting scFvs more likely to be specific for the receptor interaction region on FGF1. After three rounds of panning, bacterial supernatants of 368 randomly picked clones were screened for FGF1 binding and 51 FGF1-specific clones were identified based on signal intensity in ELISA assay with immobilized FGF1 (Figure 1a–d). Next, the clones were further validated for binding to FGF1 with the use of biolayer interferometry (BLI). Among tested clones, 30 showed favorable binding profiles (Figure 1e–h) and their nucleotide sequences were analyzed, revealing that several clones shared the same sequence. The overall analysis enabled us to distinguish 10 unique amino acid sequences of FGF1-binding scFvs.
2.2. Purification of the Generated FGF1-Specific scFvs

We have chosen three scFv variants (named: scFvA, scFvC, and scFvD), based on their FGF1-binding properties and distinct amino acid sequences in the CDR2 and CDR3 loops of the heavy and light antibody chains, that are particularly important in making contacts with the antigen. The scFvs were expressed in HB2151 E. coli cells, and efficiency of their production varied from 3.2 to 29.7 mg from one liter of bacterial culture (Table S1). The proteins were purified using Protein A affinity chromatography. Purified scFv fragments were analyzed by gel electrophoresis under reducing conditions, followed by Coomassie brilliant blue staining and anti-c-myc Western blotting (Figure 2a,b). The calculated molecular weights of the recombinant proteins were confirmed using MALDI-MS analysis (Figure 2c). All scFv fragments showed similar purification results.
2.3. Characterization, Analysis of Binding to FGF1 and Kinetic Parameters of the Selected scFvs

Binding of the antibody fragments (scFvs A, C, and D) to the FGF1 protein was analyzed by the SAR-by-NMR method using the $^{15}$N labeled FGF1. In all recorded NMR spectra the chemical shifts of a high number of FGF1 NH signals were perturbed upon titration of $^{15}$N FGF1 with the scFvs (Figure 3a). scFv-induced changes were mostly detected by the broadening of the NMR signals and reduction of signal intensities, indicating complex formation. Quantification of scFvs binding to FGF1 was not possible, since a large number of FGF1 NH signals disappeared upon addition of scFv, with complete lack of signal in the HMQC spectra with higher than equimolar amounts of scFv. Formed FGF1-scFv complex is approximately twice the molecular weight of free FGF1, and thus extensive peak broadening leads to loss of signals. The HMQC NMR results are further supported by the $^1$H NMR spectra (Figure 3b).

To test if the generated scFvs bind specifically to properly folded FGF1, we performed ELISA assay with immobilized native FGF1. Thermally denatured FGF1 and native FGF2 were used as controls for scFv binding specificity (Figure 4). We confirmed that all three antibody fragments (scFvs A, C, and D) recognized native FGF1, without binding structurally similar FGF2.

The affinity to FGF1 and the parameters of the analyzed scFvs were determined with BLI kinetic measurements. We observed strong binding of the antibody fragments to FGF1 chemically immobilized on the sensor (Figure 5a–c). The data were fitted using a bivalent analyte interaction model, due to the fact that the antibody fragments can partly associate to form a mixture of dimers and monomers. The calculation of the kinetic parameters revealed that the selected scFvs displayed high binding affinities with $K_D$ values in the nano- and micromolar range, as summarized in Table 1.
To test if the generated scFvs bind specifically to properly folded FGF1, we ... at distinct epitopes, or if the first scFv precluded the second scFv from binding to the ligand (Figure 6a,b).

Subsequent measurements, pairs of scFvs were tested for binding to chemically immobilized FGF1. Subsequent distinct or overlapping, epitope binning was performed with the use of BLI method. In a series of BLI affinities with KD values in the nano- and micromolar range, as summarized in Table 1.

The calculation of the kinetic parameters revealed that the selected scFvs displayed high binding the fact that the antibody fragments can partly associate to form a mixture of dimers and monomers.

A, C, and D) recognized native FGF1, without binding structurally similar FGF2.

We confirmed that all three antibody fragments (scFvs controls for scFv binding specificity (Figure 4). To verify if the regions within FGF1 to which selected monoclonal antibody fragments bind are distinct or overlapping, epitope binning was performed with the use of BLI method. In a series of BLI measurements, pairs of scFvs were tested for binding to chemically immobilized FGF1. Subsequent incubation of FGF1 with different scFv was used to verify if scFvs were able to bind FGF1 simultaneously at distinct epitopes, or if the first scFv precluded the second scFv from binding to the ligand (Figure 6a,b).

Table 1. Kinetic constants of the generated anti-FGF1 scFvs.

| scFv  | $K_d$ [nM] | $K_a$ [M$^{-1}$] | $K_d$ [nM] | $k_{off}$ [s$^{-1}$] |
|-------|------------|----------------|------------|---------------------|
| scFvA | 1.41 × 10$^{-7}$ | 2.14 × 10$^4$ | 8.32 × 10$^{-7}$ | 2.58 × 10$^{-1}$ |
| scFvB | 2.98 × 10$^{-7}$ | 1.35 × 10$^4$ | 3.32 × 10$^{-7}$ | 2.05 × 10$^{-1}$ |
| scFvC | 9.21 × 10$^{-7}$ | 6.93 × 10$^4$ | 6.93 × 10$^{-7}$ | 1.35 × 10$^1$ |
| scFvD | 1.21 × 10$^{-7}$ | 6.93 × 10$^4$ | 6.93 × 10$^{-7}$ | 1.35 × 10$^1$ |
| scFvE | 2.13 × 10$^{-7}$ | 1.35 × 10$^4$ | 4.36 × 10$^{-7}$ | 4.49 × 10$^0$ |
| scFvF | 3.32 × 10$^{-7}$ | 1.35 × 10$^4$ | 8.32 × 10$^{-7}$ | 2.58 × 10$^{-1}$ |
| scFvG | 2.98 × 10$^{-7}$ | 1.35 × 10$^4$ | 3.32 × 10$^{-7}$ | 2.05 × 10$^{-1}$ |

To verify if the regions within FGF1 to which selected monoclonal antibody fragments bind are distinct or overlapping, epitope binning was performed with the use of BLI method. In a series of BLI measurements, pairs of scFvs were tested for binding to chemically immobilized FGF1. Subsequent incubation of FGF1 with different scFv was used to verify if scFvs were able to bind FGF1 simultaneously at distinct epitopes, or if the first scFv precluded the second scFv from binding to the ligand (Figure 6a,b).
As a result of the study two independent binding epitopes on FGF1 were distinguished. We found that among three tested scFvs, two of them: scFvC and scFvD share a binding site on FGF1 and compete in binding it, and scFvA binds non-overlapping epitopes on the ligand. In the next step we verified if the scFvs were able to compete with FGFR1 for FGF1 binding. For this approach we used immobilized recombinant ECD_FGFR1-Fc protein and analyzed binding of premixed scFvs-FGF1 complexes, with scFvs or FGF1 only, serving as controls. The experiments revealed that the generated antibody fragments decrease the ability of FGF1 to bind to its receptor (Figure 6c–f).

| Protein | $K_D$ [M] | $k_{a1}$ [M$^{-1}$s$^{-1}$] | $k_{d1}$ [s$^{-1}$] | $K_D$ [M] | $k_{a2}$ [M$^{-1}$s$^{-1}$] | $k_{d2}$ [s$^{-1}$] |
|---------|-----------|-----------------------------|-------------------|-----------|-----------------------------|-------------------|
| scFvA   | $1.41 \times 10^{-6}$ | $2.98 \times 10^4$ | $8.32 \times 10^{-2}$ | $3.32 \times 10^{-5}$ | $1.35 \times 10^1$ | $4.49 \times 10^{-4}$ |
| scFvC   | $9.21 \times 10^{-6}$ | $9.60 \times 10^3$ | $4.19 \times 10^{-2}$ | $2.05 \times 10^{-6}$ | $2.13 \times 10^2$ | $4.36 \times 10^{-4}$ |
| scFvD   | $1.21 \times 10^{-6}$ | $2.14 \times 10^4$ | $2.58 \times 10^{-2}$ | $1.35 \times 10^{-5}$ | $6.93 \times 10^1$ | $1.35 \times 10^{-5}$ |

Figure 6. Epitope binning of selected scFvs with FGF1 and ECD_FGFR1-Fc. (a,b) Representative sensograms showing binding of subsequent scFvs to FGF1 immobilized on the sensor. scFvC blocking the ability of scFvD to bind FGF1, and scFvA binding FGF1 in the presence of scFvD; (c–e) Binding of FGF1 (blue), FGF1-scFv complex (green), and scFv (grey) to ECD_FGFR1-Fc immobilized on the sensor; (f) Percent of blocking of FGF1 binding to ECD_FGFR1-Fc by the selected antibody fragments. The error bars indicate standard deviation.

2.4. Reformatting of the scFv Antibody Fragments to the scFv-Fc Fusions

To increase the size and valency of the selected antibody fragments and therefore improve their avidity, we cloned scFvs A, C, and D into the scFv-Fc format. The Fc-fusions were designed by introducing the CH2 and CH3 domains of human IgG1 to the scFv constructs. scFv-Fc fusion proteins
were expressed using transient transfection in CHO-S cells, resulting in moderate to high yields of recombinant protein expression (Table S2). Protein production was followed by a single-step affinity chromatography purification on Protein A resin with SDS-PAGE and Coomassie blue staining, anti-Fc Western blotting, and mass spectrometry analysis (Figure 7a–c). All scFvs-Fc showed the same purity level, estimated to be above 95%.

2.5. Kinetic Parameters of the scFv-Fc Antibody Fragments

As described in Section 2.3, for the scFvs, the affinity to FGF1 and the parameters of the selected scFv-Fc antibody fragments were measured with BLI and analyzed in the same manner. As expected, the bivalent antibody format demonstrated enhanced binding to FGF1, compared to the parental scFv, with binding affinities improved from 3- to 17-fold and reaching the nanomolar range (Figure 8a–c).

![Figure 7. Purification and analysis of scFv-Fc fusions at an example of scFvD-Fc. (a) SDS-PAGE and Coomassie brilliant blue staining of the scFv-Fc purification steps; (b) Western blot analysis of the scFv-Fc purification process. The membrane was stained with anti-human IgG Fc fragment HRP-conjugated antibody; (c) The representative mass spectrum of purified scFv-Fc. The detected m/z peaks correspond to a covalent dimer and monomer of the scFv-Fc protein.](image)

![Figure 8. Sensograms for binding of serial two-fold dilutions of scFvs-Fc to FGF1. (a–c) Chemically immobilized FGF1 was used to capture analyzed scFvs-Fc, and the dissociation was measured in KB buffer.](image)
To explore the effects of generated antibody fragments on FGF1 mitogenic activity, FGF1-dependent cell proliferation was examined. The mouse fibroblast NIH/3T3 cells were treated with selected scFvs and scFvs-Fc without (Figure S1a) and in the presence of FGF1 and heparin (Figure 9a). By trapping FGF1, five selected antibody fragments—scFvs C and D, together with scFvs A-Fc, C-Fc, and D-Fc, efficiently inhibited NIH/3T3 cell proliferation, from 22 to 91%. Generated antibody fragments were further tested in FGFR1-expressing BaF3-R1 cells, in which scFvs-Fc also displayed significant activity (cell proliferation inhibition from 62 to 100%, as shown in Figure 9b), similar to the ECD_FGFR1-Fc ligand trap control (Figure S1b). The lack of effect for the scFvs may result from overall lower stability of this format in a long-term assay. This may also be the case for scFvA tested in NIH/3T3 cells, as it inhibits cell proliferation only as the Fc fusion. Finally, we also achieved a strong antimitogenic activity of the generated antibody fragments on G-292, FGFR1-positive, human osteosarcoma cancer cell line (Figure 9c), confirming their ability to efficiently bind FGF1 and preclude its binding to FGFR1 in in vitro model, without having any effect in the absence of FGF1 (Figure S1c). The results obtained for the cancer cell line were consistent with the data for fibroblast cells, showing the most significant effect for scFvs B and C, together with all generated scFvs-Fc. Similarly to NIH/3T3 cells, all antibody fragments except scFvA, showed complete proliferation inhibition.

![Figure 9](image-url)

**Figure 9.** Antimitogenic FGF1 activity of selected antibody fragments tested on (a) NIH/3T3; (b) BaF3-R1; and (c) G-292 cell lines. The cells were starved for 24 h and incubated with scFvs (green) or scFvs-Fc (blue) in the presence of FGF1 and heparin, with cells without any treatment (light grey), and cells incubated with FGF1 and heparin only (dark grey), serving as controls. After 48 h of incubation, the cell proliferation level was determined. The error bars show standard deviation.
3. Discussion

FGF1 is a strong mitogenic agent, important in angiogenesis, tissue regeneration, and the inflammation processes [8,27]. The role of FGF1 signaling in cancer is widely studied [6,19,28,29]. Preclinical and clinical evidences indicate that blocking aberrant FGF/FGFR signaling may represent a promising strategy for the therapy of human cancers [30]. Efforts targeting this pathway have led to the development of numerous small molecule FGFR inhibitors with wide implications for cancer therapy [9]. These tyrosine kinase inhibitors show varied effects in clinical trials, with the response being highly dependent on tumor genetic characteristics [31].

Another group of therapeutics consists of antibodies and FGF traps that represent a novel class of compounds with promising therapeutic features. Their advantages over the TKIs are low dosage and toxicity, high activity, and amino acids being their metabolic end products. There are several monoclonal antibody fragments currently being investigated in preclinical and early phase development studies [30,32]. The examples include: GP369, an antibody specific for FGFR2, or BAY1187982—an anti-FGFR2 antibody-drug conjugate, that both have shown successful results on gastric and breast cancer models [12,33]. Another drug, MFGFR1877S, a monoclonal antibody targeting FGFR3 has demonstrated promising activity in preclinical models of urothelial carcinoma [15], although failed to work in clinical studies of multiple myeloma treatment.

Ligand traps, on the other hand, target soluble growth factors, and by sequestering them prevent activation of FGFRs on cancerous cells. This group is represented by natural FGFs binders, such as heparin, thrombospondin-1 (TSP-1), or longpentraxin-3 (PTX-3) [34], as well as soluble decoy FGFRs [17,35] and synthetic molecules able to bind FGFs, e.g., heparin-like polyanionic molecules [36] and anti-FGF1 antibodies [20–22]. To date, among the listed FGF traps, a promising molecule is FP-1039, a soluble FGFR1-Fc fusion protein that binds almost all FGFs, and thus inhibits growth of different tumor cell lines, including lung and endometrial cancer, as well as mesothelioma cell lines [35,37]. FP-1039 inhibits in vivo growth of different tumor models, shows low toxicity, and is currently tested in phase I clinical trial [16].

Among anti-FGF antibodies developed for therapeutic applications, FGF2 is the most commonly chosen target for selection of antibodies or antibody fragments [20–22], but there are also few reports on anti-FGF1 [24,38], anti-FGF8b [23], and anti-FGF23 [25]. Regarding antibodies binding FGF1, there is a scFv1C9 developed by the group of Xiao-Juan Zhu [24,38,39]. This small antibody is based on hybridoma derived from mouse immunized with FGF1 and inhibits growth of breast and glioma tumors in vitro and in vivo. Our experimental approach presented here for the identification of FGF1-binding scFv variants differs significantly, as they were selected from scFv library with the use of phage display. Additionally, the binders were counterselected against receptor-binding deficient FGF1 mutant to maximize the probability of selected scFv clones binding in the FGFR-FGF1 interface and thus interrupting receptor–ligand interaction.

In this study we developed a panel of antibody fragments capable of binding and neutralizing the activity of FGF1. We have selected this target, as the activity of FGF1 is related to the activation of all four FGF receptor isoforms [40], thus the potential of the generated antibody fragments can be more widely exploited. The binders were obtained by optimizing a well-established selection procedure from Tomlinson I and J libraries [41]. scFv—a widely used antibody format has several advantages over the full-length monoclonal antibodies, such as easier production, or improved penetration into tumor tissue [42]. Three scFv clones, named scFvA, C, and D, showing best binding properties, were selected for further experiments. First, we validated scFv binding to FGF1 by SAR-by-NMR measurements. The SAR-by-NMR method is based on monitoring the chemical shift changes in protein amide backbone resonances upon addition of an interacting agent [43–45]. For all tested scFvs we have observed changes in NH chemical shifts of $^{15}$N-FGF1, mostly by the broadening of the NMR signals and reduction of signal intensities due to complex formation, implying an intermediate chemical exchange rate on the NMR timescale [44–46]. Moreover, generated antibody fragments showed high selectivity against FGF1, with micro- and nanomolar dissociation constants, as established by BLI measurements.
In the next stage of our study we have reformatted the scFv fragments to the scFc-Fc fusion format. In line with our expectations and previous experience, this conversion resulted in significant improvement of the affinity to FGF1, lowering the dissociation constants by 3- to 17-fold. Moreover, when considering the future therapeutic applications, the scFv-Fc format displays several advantages, that include higher valency and larger size of the antibody fragments. It results in prolonged circulation half-life, bivalent binding, and possessing the ability to induce antibody-dependent cell-mediated cytotoxicity [47].

To explore the value of generated FGF1 traps as therapeutic agents, we determined their capacity to inhibit the FGF1-induced proliferation of FGFR-expressing cells. We performed cell proliferation assays on fibroblast NIH/3T3 cells, which are known to express FGFR1 and are the most responsive cells with regard to FGF1-induced mitogenic effects, and therefore optimal for proliferation assays. Additionally, we have tested BaF3-R1 pro B cells, overexpressing FGFR1 with Ig-like domain III in c splice form [48]. BaF3-FGFR1 cells respond well to FGF1 stimulation (similarly to NIH/3T3) and are therefore a good model of FGFR-overexpressing cancers for in vitro proliferation assays. In the next step we have examined the effect of selected antibody fragments on FGF1 trapping in human osteosarcoma G-292 cancer cell line. We demonstrated that all generated scFv-Fc fusions potently suppressed the FGF1-induced cell proliferation of all: fibroblast NIH/3T3 cells, transfected BaF3-R1 cells, and FGFR1-expressing G-292 cells. We did not observe antiproliferative activity for scFvA in the NIH/3T3 and G-292 models, and for the scFv fragments A, C, and D in the BaF3-R1 cells, presumably due to a possible lower stability of scFv format compared to Fc-fusions. Yet, two of the tested scFvs (C and D) have shown inhibitory effect on NIH/3T3, and G-292 proliferation.

In general, generated antibody fragments in Fc-fusion format effectively neutralized the mitogenic activity of FGF1, and the level of cell proliferation showed dramatic reduction up to 100% for the scFvA-Fc in the BaF3-R1 model, and for the majority of tested antibody fragments in the G-292 model.

Summarizing, with the use of an optimized phage display method and subsequent reformatting, we have generated highly potent anti-FGF1 antibody fragments, exhibiting high affinity and specificity towards the antigen. Our data clearly indicate that the developed antibody fragments acting as FGF1 ligand traps can serve as potent therapeutic agents for the treatment of FGF1-dependent cancers. Further studies on cancer cell lines continued in in vivo xenograft models will be essential to future development of generated anti-FGF1 molecules.

4. Materials and Methods

4.1. Proteins

4.1.1. FGF1 and FGF1 Mutant Y94A/N95A

Recombinant FGF1 (Met-Ala-FGF122−155) was produced at 37 °C in an E. coli BL21(DE3)pLysS strain and purified on a heparin-sepharose CL-6B column following a described procedure [49,50]. FGF1 mutant Y94A/N95A was designed by Zakrzewska et al. [26]. The recombinant protein was expressed and purified in the same manner as for FGF1.

4.1.2. 15N FGF1

15N-FGF1 for NMR measurements was expressed in E. coli BL21(DE3)Rosetta grown in minimal medium containing 15N-NH4Cl as nitrogen source. 30 mL of preculture in LB medium was centrifuged, washed, and used to inoculate minimal medium M9 with 15N-NH4Cl and 0.4% glucose. Cells were grown at 37 °C to OD600 = 1.2 and induced with 0.5 mM IPTG. Protein expression was conducted for 16 h at 30 °C. Protein from soluble fraction was purified on a heparin-sepharose CL-6B column similarly to wild-type FGF1.
4.1.3. FGF2

Recombinant, 133 amino acid truncated form of FGF2 was expressed at 25 °C in E. coli BL21(DE3)pLysS and purified by affinity chromatography as described by Swiderska et al. [51].

4.1.4. ECD_FGFR1-Fc

Human IgG1 Fc fusion of the full length extracellular domain of FGFR1 (ECD_FGFR1-Fc) expression was carried out according to Sokolowska-Wedzina et al. [52] with minor modifications. Briefly, CHO-S cells (Invitrogen, Carlsbad, CA, USA) were cultured at 37 °C in a shaking incubator at 110 rpm with 8% CO₂ in PowerCHO-2CD medium (Lonza, Basel, Switzerland) supplemented with 8 mM L-glutamine and 1× penicillin/streptomycin solution (Biowest, Riverside, MO, USA). On the day of transfection the culture was centrifuged and cell pellet was resuspended in ProCHO4 medium (Lonza). Appropriate amount of ECD_FGFR1-Fc encoding plasmid (1.25 µg of DNA per every 1 × 10⁶ cells) was resuspended in 150 mM NaCl, mixed and incubated for 10 min at RT with a proper amount of linear polyethylenimine (PEI; Polyscience, Warrington, PA, USA) and diluted in 150 mM NaCl (5 µg of PEI per each 1 × 10⁶ cells). The final volume of the DNA and PEI solution corresponded to 10% of the total cell suspension volume. The DNA and PEI complexes were added to the cell solution. The transfection procedure was carried out for 4 h at 37 °C, 110 rpm, and 8% CO₂. After this time, the culture was diluted with an equal volume of PowerCHO-2CD supplemented with 8 mM L-glutamine and 2× penicillin-streptomycin solution and incubated at 32 °C, 110 rpm, and 8% CO₂. On the second day of protein production, the CHO-S culture was supplemented with L-glutamine to the final concentration of 4 mM. The cells were harvested on the tenth day of expression. The purification of the ECD_FGFR1-Fc protein was performed following a described procedure, using affinity chromatography rProtein A Sepharose Fast Flow Resin (GE Healthcare, Little Chalfont, UK) [52].

4.2. Phage Display Selection of scFv Antibody Fragments

The selection procedure was based on a Tomlinson I and J libraries protocol [41] and was performed as follows. The 96-well Nunc Maxi Sorp plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated overnight at 4°C with 100 µg/mL of FGF1 or FGF1 Y94A/N95A in PBS. After washing and blocking with 2% MPBS (Marvel milk in PBS) the counterselection wells coated with FGF1 Y94A/N95A were incubated with 10¹² phage particles from the Tomlinson I and J libraries (Source BioScience, Nottingham, UK), blocked with 2% MPBS, for 40 min with rotation (600 rpm) and 80 min standing at 4°C. The phage particles were then transferred to the washed and blocked selection wells coated with FGF1 and incubated as described for FGF1 Y94A/N95A. The wells were then washed 10 times with PBS-0.1% Tween 20 and 10 times with PBS (15 and 20 times for each buffer for the subsequent rounds). For panning rounds 1 and 2 the bound phage was eluted with 100 mM triethylamine (TEA) and neutralized with 1 M Tris-HCl, pH 7.2. In the third round the selected phage particles were unbound from the ligand for 3 h by elution with 2-times molar excess of ECD_FGFR1-Fc over the immobilized FGF1. The second elution step in this round was performed with TEA as in the previous rounds. Propagation of phage after each round of panning was carried out as described by Viti et al. [53] and Lee et al. [41]. The monoclonal ELISA of soluble scFv antibody fragments was carried out according to Sokolowska-Wedzina et al. [54].

4.3. Biolayer Interferometry Screening of scFv Antibody Fragments

Bacterial supernatants containing soluble scFvs (the same samples as used for ELISA) were filtered through 0.22 µm filters and screened for binding to FGF1 by biolayer interferometry. BLI experiments were performed on an Octet K2 instrument (Fortebio Inc., Menlo Park, CA, USA) using amine-reactive (AR2G) sensors. Sensor tips were hydrated for 15 min prior to use. The sensors were then activated with a freshly prepared mixture of 20 mM EDC and 10 mM sulfo-NHS, coupled with 20 µg/mL
FGF1 in 10 mM sodium acetate, pH 6.0, and then excess reactive esters were blocked with 1 M ethanolamine, pH 8.5. Amine-coupled FGF1 was then used to capture scFvs present in the filtered bacterial supernatants. Association and dissociation from the ligand were both monitored for 180 s each. Surfaces were regenerated with 100 mM glycine, pH 4.5, and the assay was repeated. ForteBio’s Data Analysis 9.0 software was used for the analysis of the binding curves.

4.4. Purification and Analysis of scFv Antibody Fragments

scFv antibody fragments were prepared according to Sokolowska-Wedzina et al. [54]. Briefly, purified pIT2 plasmids with scFv sequences were electroporated into E. coli HB2151 cells (Source BioScience). The bacteria were grown in 2× TY media supplemented with 100 µg/mL ampicillin and 0.1% glucose to OD600 = 0.8 and the production of protein was induced with 0.5 mM IPTG. Cells were cultured at 30 °C, 180 rpm, overnight and then the cultures were harvested, centrifuged twice at 4000 rcf, 4 °C for 40 min, and filtered using a Stericap PLUS bottle filter device (Merck Millipore, Darmstadt, Germany). scFv antibody fragments were purified from the supernatants by affinity chromatography using rProtein A Sepharose Fast Flow Resin (GE Healthcare), following the same protocol as described previously by our group for ECD_FGFR-Fc proteins [52]. Purified scFvs were analyzed by SDS-PAGE, Western blotting using anti-c-myc antibody, clone 9E10 (Santa Cruz Biotechnology Inc., Dallas, TX, USA), and mass spectrometry. The molecular masses of the proteins were verified by MALDI-TOF/TOF 4800 (Applied Biosystems, Foster City, CA, USA), using α-cyano-4-hydroxycinnamic acid as a matrix.

4.5. Nuclear Magnetic Resonance Measurements

NMR spectra were measured for the 200 µL samples of 0.2 mM free 15N FGF1, 0.1 mM free scFv, and 0.1–0.12 mM FGF1-scFv complex. FGF1 protein was in 25 mM Tris-HCl, pH 7.5, 2 M NaCl, and 1 mM EDTA, and scFvs were in PBS buffer. 10% (v/v) D2O was added to the samples to provide a lock signal. All spectra were recorded at 300 K using an Avance 600 MHz spectrometer (Bruker, Billerica, MA, USA). 1H–15N heteronuclear correlations were obtained using the SOFAST HMQC pulse sequence [55].

4.6. Cross-Reactivity Assay

The Nunc Maxi Sorp 96-well plates were coated overnight at 4 °C with 50 µg/mL of FGF1, FGF1 previously thermally denatured by heating to 98 °C for 5 min, or FGF2 in PBS buffer. Next, the wells were washed with PBS and blocked with 2% MPBS for 100 min and after second washing with PBS, 10 µg/mL of scFvs were added to the wells and incubated for 60 min at 4 °C. The unbound proteins were washed and anti-c-myc mouse monoclonal antibody, clone 9E10 (Abcam, Cambridge, UK) was added to wells and incubated for 60 min at RT. The wells were washed with PBS and a secondary goat anti-mouse IgG antibody conjugated with horseradish peroxidase (115-035-003, Jackson ImmunoResearch, West Grove, PA, USA) was used. ELISA was developed using TMB liquid substrate (Sigma-Aldrich, Saint Louis, MO, USA). The reaction was stopped with 1 M H2SO4 and the absorbance was measured at 450 and 650 nm. The obtained absorbance values were a result of A650 background subtraction from A450.

4.7. Biolayer Interferometry Studies of FGF1 Binding Affinity

The kinetics of binding of antibody fragments to FGF1 were measured on an Octet K2 instrument at 25 °C with FGF1 being immobilized on the AR2G sensor surface in the same manner as described in 4.3. Measurements were performed in the PBS-based Kinetics Buffer (KB; ForteBio Inc.), association and dissociation of the analyte to and from the ligand were monitored for 300 s or 180 s for scFvs and scFvs-Fc, respectively. Sensor surfaces were regenerated with 100 mM glycine, pH 4.0. All measurements were performed in duplicate. The kinetic data were fitted and analyzed with
the BIAevaluation 4.1 software (GE Healthcare) using a Bivalent analyte binding model \cite{56,57} and respective rate constants (\(k_{on}\) and \(k_{off}\)) and \(K_D\) values were calculated.

4.8. Epitope Binning with Biolayer Interferometry

FGF1 was immobilized on AR2G sensors as described in 4.3. Measurements were performed in the Kinetics Buffer. Amine-coupled FGF1 was used to capture first scFv at 200 nM for 180 s and then the sensor was moved to the well with the second scFv prepared at the same concentration and the following association was measured for further 180 s. The surface was regenerated with 100 mM glycine, pH 3.5, and the assay was repeated for another scFv-scFv pair. The measurements were continued until all available scFv-scFv configurations were examined. For the scFv-FGFR1 epitope binning assay, ECD_FGFR1-Fc was coupled with activated AR2G sensors, as described for FGF1 in 4.3., at 5 \(\mu\)g/mL in 10 mM sodium acetate, pH 5.0. FGF1 at 1 \(\mu\)M was preincubated with scFv fragment at 1:1 molar ratio for 30 min, and then the ability of complexed FGF1 to bind to the immobilized ECD_FGFR1-Fc was assessed. The sensor surface was regenerated with 100 mM glycine, pH 2.5, and the assay was repeated for the remaining FGF1-scFv complexes. Binding of FGF1 only and unspecific binding of scFvs to the immobilized protein was also verified. All measurements were performed in duplicate. The binding curves were analyzed using ForteBio’s Data Analysis 9.0 software.

4.9. scFv-Fc Fusions Preparation, Purification and Analysis of the Proteins

The scFv-Fc constructs were prepared as described by Sokolowska-Wedzina et al. \cite{54}. Briefly, sequences encoding secretion signal peptide (SSP) and the HindIII and Kpn2l restriction sites were introduced into the scFv DNA sequences in two PCR reactions. In the next step, amplified scFv DNA and pLEV113-Fc expression vector (LakePharma, Belmont, CA, USA), encoding the Fc domain of human IgG1 \cite{52}, were digested using HindIII and Kpn2l restriction enzymes (Thermo Fisher Scientific), and then the PCR product was ligated with the vector with the use of T4 DNA ligase (Thermo Fisher Scientific). The resulting construct, inserted into a pLEV113 expression vector, was used to stably transfect CHO-S cells. scFv-Fc fusion proteins prepared with a secretion signal peptide were expressed and purified using affinity chromatography following the procedure described for the ECD_FGFR-Fc proteins \cite{52}. The proteins were analyzed by SDS–PAGE, Western blotting using anti-human IgG Fc-HRP-conjugated antibody (ab97225, Abcam) and mass spectrometry.

4.10. Cell Proliferation Studies

Mouse embryo fibroblast NIH/3T3 and human osteosarcoma G-292 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA), whereas the BaF3-R1 (isoform IIIc) cell line was provided by David M. Ornitz from Washington University (St. Louis, MO, USA). NIH/3T3 and G-292 cells were seeded in a 96-well flat-bottomed plates (VWR, Radnor, PA, USA) at a density of \(1 \times 10^4\) cells/well in Dulbecco’s modified Eagle’s medium (DMEM, Biowest) supplemented with 10% fetal bovine serum (FBS, Biowest) and 1\% penicillin/streptomycin solution (Biowest), while BaF3-R1 cells were seeded in a 96-well flat-bottomed plates (VWR) at \(3 \times 10^4\) cells/well in RPMI 1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% bovine calf serum (BCS; Sigma-Aldrich), 1\% penicillin/streptomycin solution (Biowest), 50 \(\mu\)M \(\beta\)-mercaptoethanol (Sigma-Aldrich), 4 mM L-glutamine (Biowest), and 0.5 ng/mL recombinant murine interleukin 3 (IL-3, PeproTech, Rocky Hill, NJ, USA) and incubated at 37 \(^\circ\)C in a humidified incubator with 5% CO\(_2\) for 16 h. The cells were then washed with PBS and starved for 24 h in 80 \(\mu\)L/well of the same medium without the addition of FBS for NIH/3T3 and G-292, or IL-3 for BaF3-R1, respectively. 20 \(\mu\)L of activation medium containing FGF1 and heparin (Sigma-Aldrich) was added to the wells to the final concentrations of 5 ng/mL and 10 U/mL, respectively. scFvs and scFvs-Fc in 50 \(\mu\)L/well were added to the wells to a final concentration of 100 \(\mu\)g/mL and cells were allowed to proliferate at 37 \(^\circ\)C, 5% CO\(_2\) for 48 h. Cell viability was measured using AlamarBlue or PrestoBlue reagent (Thermo Fisher Scientific), according to the manufacturer’s directions. Fluorescence emission was measured using an EnVision Multilabel Reader (PerkinElmer,
Waltham, MA, USA). Each sample dilution was prepared in triplicate and every experiment was repeated on three independent plates.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/9/2470/s1.

Author Contributions: J.C.: Experiment design, execution, analysis, figures, manuscript preparation, editing, and revision; A.S.: Experiment execution, analysis, manuscript editing, and revision; M.Z.: Manuscript revision and proof-reading; M.C.: Analysis and interpretation of NMR data; M.P.: Acquisition of NMR data; T.A.H.: NMR experiment analysis, manuscript revision; J.O.: Experiment design, manuscript revision, and proof-reading.

Acknowledgments: The authors thank Łukasz Opalinski and Daniel Krowarsch for valuable scientific discussions, Piotr Jakimowicz for skillfully performing mass spectrometry analysis, and David M. Ornitz for kindly providing BaF3-R1 cell line. This work was funded by the National Science Centre, Poland: research grant SYMFONIA 2014/12/W/NZ1/00457. Publication costs were supported by Wroclaw Center of Biotechnology program “The Leading National Research Center (KNOW) for years 2014-2018”.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

| Acronym | Abbreviation |
|---------|--------------|
| BLI     | Biolayer interferometry |
| CDR     | Complementarity determining region |
| CHO     | Chinese hamster ovary |
| ECD     | Extracellular domain |
| EGFR    | Epidermal growth factor receptor |
| ELISA   | Enzyme-linked immunosorbent assay |
| Erk1/2  | Extracellular signal-regulated kinases 1/2 |
| Fc      | Fragment crystallizable |
| FGF1    | Fibroblast growth factor 1 |
| FGF1    | Fibroblast growth factor receptor |
| HMQC    | Heteronuclear multiple-quantum correlation |
| HRP     | Horseradish peroxidase |
| IB      | Immunoblotting |
| KB      | Kinetics buffer |
| MALDI   | Matrix-assisted laser desorption/ionization |
| MS      | Mass spectrometry |
| NMR     | Nuclear magnetic resonance |
| RT      | Room temperature |
| RTK     | Receptor tyrosine kinase |
| SAR     | Structure-activity relationships |
| scFv    | Single chain Fragment variable |
| SDS-PAGE| Sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| TEA     | Triethylamine |
| TKI     | Tyrosine kinase inhibitor |
| VEGFR   | Vascular endothelial growth factor receptor |

References

1. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P.T.; Roydasgupta, R.; Kuo, W.L.; Lapuk, A.; Neve, R.M.; Qian, Z.; Ryder, T.; et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell* **2006**, *10*, 529–541. [CrossRef] [PubMed]

2. Gelsi-Boyer, V. Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer. *Mol. Cancer Res.* **2005**, *3*, 655–667. [CrossRef] [PubMed]

3. Weiss, J.; Sos, M.L.; Seidel, D.; Peifer, M.; Zander, T.; Heuckmann, J.M.; Ullrich, R.T.; Menon, R.; Maier, S.; Soltermann, A.; et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci. Transl. Med.* **2010**, *2*. [CrossRef] [PubMed]
4. Tsujimoto, H.; Sugihara, H.; Hagiwara, A.; Hattori, T. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. *Virchows Arch.* 1997, 431, 383–389. [CrossRef] [PubMed]

5. Hanker, A.B.; Garrett, J.T.; Estrada, M.V.; Moore, P.D.; Ericsson, P.G.; Koch, J.P.; Langley, E.; Singh, S.; Kim, P.S.; Frampton, G.M.; et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. *Clin. Cancer Res.* 2017, 23, 4323–4334. [CrossRef] [PubMed]

6. Hallinan, N.; Finn, S.; Cuffe, S.; Rafee, S.; O’Byrne, K.; Gately, K. Targeting the fibroblast growth factor receptor family in cancer. *Cancer Treat. Rev.* 2016, 46, 51–62. [CrossRef] [PubMed]

7. Eswarakumar, V.P.; Lax, I.; Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. *Cytokine Growth Factor Rev.* 2005, 16, 139–149. [CrossRef] [PubMed]

8. Presta, M.; Dell’Era, P.; Mitola, S.; Moroni, E.; Ronca, R.; Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine Growth Factor Rev.* 2005, 16, 159–178. [CrossRef] [PubMed]

9. Katoh, M. Therapeutics Targeting FGF Signaling Network in Human Diseases. *Trends Pharmacol. Sci.* 2016, 37, 1081–1096. [CrossRef] [PubMed]

10. Hudis, C.A. Trastuzumab—Mechanism of Action and Use in Clinical Practice. *N. Engl. J. Med.* 2007, 357, 39–51. [CrossRef] [PubMed]

11. Porta, R.; Borea, R.; Coelho, A.; Khan, S.; Araújo, A.; Reclusa, P.; Franchina, T.; Van Der Steen, N.; van Dam, P.; Ferri, J.; et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. *Crit. Rev. Oncol. Hematol.* 2017, 113, 256–267. [CrossRef] [PubMed]

12. Bai, A.; Meetze, K.; Vo, N.Y.; Kollipara, S.; Mazzu, E.K.; Winston, W.M.; Weiler, S.; Poling, L.L.; Chen, T.; Ismail, N.S.; et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. *Cancer Res.* 2010, 70, 7630–7639. [CrossRef] [PubMed]

13. Zhao, W.; Wang, L.; Park, H.; Chhim, S.; Tanphanich, M.; Yashiro, M.; Kim, K.J. Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts. *Clin. Cancer Res.* 2010, 16, 5750–5758. [CrossRef] [PubMed]

14. Inokuchi, M.; Fujimori, Y.; Otsuki, S.; Sato, Y.; Nakagawa, M.; Kojima, K. Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer. *Gastroenterol. Res. Pract.* 2015, 2015. [CrossRef] [PubMed]

15. O’Donnell, P.; Goldman, J.W.; Gordon, M.S.; Shih, K.; Choi, Y.J.; Lu, D.; Kabbarah, O.; Ho, W.; Rooney, L.; Lam, E.T. 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors. *Eur. J. Cancer* 2012, 48, 191–192. [CrossRef]

16. Tolcher, A.W.; Papadopoulos, K.P.; Patnaik, A.; Wilson, K.; Thayer, S.; Zanghi, J.; Gemo, A.T.; Kavanaugh, W.M.; Keer, H.N.; LoRusso, P.M. A phase I first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. *Ann. Oncol.* 2016, 27, 526–532. [CrossRef] [PubMed]

17. Li, D.; Wei, X.; Xie, K.; Chen, K.; Li, J.; Fang, J. A novel decoy receptor fusion protein for FGFR-2 potency inhibits tumour growth. *Br. J. Cancer* 2014, 111, 68–77. [CrossRef] [PubMed]

18. Taraboletti, G.; Rusnati, M.; Ragona, L.; Colombo, G. Targeting tumor angiogenesis with TSP-1-based compounds: Rational design of antiangiogenic mimetics of endogenous inhibitors. *Onctarget* 2010, 1, 662–673. [CrossRef]

19. Ronca, R.; Giacomini, A.; Rusnati, M.; Presta, M. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. *Expert Opin. Ther. Targets* 2015, 19, 1361–1377. [CrossRef] [PubMed]

20. Wang, L.; Park, H.; Chhim, S.; Ding, Y.; Jiang, W.; Queen, C.; Kim, K.J. A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts. *Mol. Cancer Ther.* 2012, 11, 864–872. [CrossRef] [PubMed]

21. Tao, J.; Xiang, J.J.; Li, D.; Deng, N.; Wang, H.; Gong, Y.P. Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. *Biochem. Biophys. Res. Commun.* 2010, 394, 767–773. [CrossRef] [PubMed]

22. Cai, Y.; Yao, S.; Zhong, J.; Zhang, J.; Jiang, H.; Deng, Y.; Deng, N. Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer. *Onctarget* 2017, 8, 20187–20197. [CrossRef] [PubMed]
23. Tanaka, A.; Furuya, A.; Yamasaki, M.; Hanai, N.; Kuriki, K.; Kamaikito, T.; Kobayashi, Y.; Yoshida, H.; Koike, M.; Fukuyama, M. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. *Cancer Res. 1998*, 58, 2053–2056. [PubMed]

24. Shi, H.-L.; Yang, T.; Deffar, K.; Dong, C.-G.; Liu, J.-Y.; Fu, C.-L.; Zheng, D.-X.; Qin, B.; Wang, J.-J.; Wang, X.-Z.; et al. A novel single-chain variable fragment antibody against FGF-1 inhibits the growth of breast carcinoma cells by blocking the intracrine pathway of FGF-1. *ILMB Life 2011*, 63, 129–137. [CrossRef] [PubMed]

25. Aono, Y.; Hasegawa, H.; Yamazaki, Y.; Shimada, T.; Fujita, T.; Yamashita, T.; Fukumoto, S. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. *J. Bone Miner. Res. 2011*, 26, 803–810. [CrossRef] [PubMed]

26. Zakrzewska, M.; Krowarsch, D.; Wiedlocha, A.; Olsnes, S.; Otlevski, J. Structural Requirements of FGF-1 for Receptor Binding and Translocation into Cells. *Biochemistry 2006*, 45, 15338–15348. [CrossRef] [PubMed]

27. Powers, C.J.; McEskey, S.W.; Wellstein, A. Fibroblast growth factors, their receptors and signaling. *Endocr. Relat. Cancer 2000*, 7, 165–197. [CrossRef] [PubMed]

28. Beenen, A.; Mohammadi, M. The FGF family: Biology, pathophysiology and therapy. *Nat. Rev. Drug Discov. 2009*, 8, 235–253. [CrossRef] [PubMed]

29. Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. *Nat. Rev. Cancer 2010*, 10, 116–129. [CrossRef] [PubMed]

30. Babina, I.S.; Turner, N.C. Advances and challenges in targeting FGFR signalling in cancer. *Mol. Med. 2014*, 18, 3259–3263. [CrossRef] [PubMed]

31. Liang, G.; Liu, Z.; Wu, J.; Cai, Y.; Li, X. Anticancer molecules targeting fibroblast growth factor receptors. *Trends Pharmacol. Sci. 2012*, 33, 531–541. [CrossRef] [PubMed]

32. Sommer, A.; Kopitz, C.; Schatz, C.A.; Nising, C.F.; Mahlert, C.; Lerchen, H.G.; Stelte-Ludwig, B.; Hammer, S.; Greven, S.; Schuhmacher, J.; et al. Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. *Cancer Res. 2016*, 76, 6331–6339. [CrossRef] [PubMed]

33. Giacomini, A.; Chiodelli, P.; Matarazzo, S.; Rusnati, M.; Presta, M.; Ronca, R. Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy. *Pharmacol. Res. 2016*, 107, 172–185. [CrossRef] [PubMed]

34. Harding, T.C.; Long, L.; Palencia, S.; Zhang, H.; Sadra, A.; Hestir, K.; Patil, N.; Levin, A.; Hsu, A.W.; Charych, D.; et al. Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer. *Sci. Transl. Med. 2013*, 5, 178ra39. [CrossRef] [PubMed]

35. Rusnati, M.; Oreste, P.; Zoppetti, G.; Presta, M. Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery. *Curr. Pharm. Des. 2005*, 11, 2489–2499. [CrossRef] [PubMed]

36. Blackwell, C.; Sherk, C.; Fricko, M.; Ganji, G.; Barnette, M.; Hoang, B.; Tunstead, J.; Skedzielewski, T.; Alsaid, H.; Jucker, B.M.; et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application. *Onco target 2017*, 8, 16052–16074. [CrossRef] [PubMed]

37. Babina, I.S.; Turner, N.C. Advances and challenges in targeting FGFR signalling in cancer. *Nat. Rev. Cancer 2017*, 17, 318–332. [CrossRef] [PubMed]

38. Liang, G.; Liu, Z.; Wu, J.; Cai, Y.; Li, X. Anticancer molecules targeting fibroblast growth factor receptors. *Trends Pharmacol. Sci. 2012*, 33, 531–541. [CrossRef] [PubMed]

39. Sommer, A.; Kopitz, C.; Schatz, C.A.; Nising, C.F.; Mahlert, C.; Lerchen, H.G.; Stelte-Ludwig, B.; Hammer, S.; Greven, S.; Schuhmacher, J.; et al. Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. *Cancer Res. 2016*, 76, 6331–6339. [CrossRef] [PubMed]

40. Ronca, R.; Rusnati, M.; Presta, M. Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery. *Curr. Pharm. Des. 2005*, 11, 2489–2499. [CrossRef] [PubMed]

41. Blackwell, C.; Sherk, C.; Fricko, M.; Ganji, G.; Barnette, M.; Hoang, B.; Tunstead, J.; Skedzielewski, T.; Alsaid, H.; Jucker, B.M.; et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application. *Onco target 2017*, 8, 16052–16074. [CrossRef] [PubMed]

42. Babina, I.S.; Turner, N.C. Advances and challenges in targeting FGFR signalling in cancer. *Nat. Rev. Cancer 2017*, 17, 318–332. [CrossRef] [PubMed]

43. Giacomini, A.; Chiodelli, P.; Matarazzo, S.; Rusnati, M.; Presta, M.; Ronca, R. Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy. *Pharmacol. Res. 2016*, 107, 172–185. [CrossRef] [PubMed]

44. Harding, T.C.; Long, L.; Palencia, S.; Zhang, H.; Sadra, A.; Hestir, K.; Patil, N.; Levin, A.; Hsu, A.W.; Charych, D.; et al. Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer. *Sci. Transl. Med. 2013*, 5, 178ra39. [CrossRef] [PubMed]

45. Rusnati, M.; Oreste, P.; Zoppetti, G.; Presta, M. Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery. *Curr. Pharm. Des. 2005*, 11, 2489–2499. [CrossRef] [PubMed]

46. Blackwell, C.; Sherk, C.; Fricko, M.; Ganji, G.; Barnette, M.; Hoang, B.; Tunstead, J.; Skedzielewski, T.; Alsaid, H.; Jucker, B.M.; et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application. *Onco target 2017*, 8, 16052–16074. [CrossRef] [PubMed]

47. Babina, I.S.; Turner, N.C. Advances and challenges in targeting FGFR signalling in cancer. *Nat. Rev. Cancer 2017*, 17, 318–332. [CrossRef] [PubMed]
42. Vaks, L.; Benhar, I. Production of stabilized scFv antibody fragments in the E. coli bacterial cytoplasm. Methods Mol. Biol. 2014, 1060, 171–184. [CrossRef] [PubMed]

43. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531–1534. [CrossRef] [PubMed]

44. Barile, E.; Pellecchia, M. NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Chem. Rev. 2014, 114, 4749–4763. [CrossRef] [PubMed]

45. Singh, M.; Krajewski, M.; Mikolajka, A.; Holak, T.A. Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J. Biol. Chem. 2005, 280, 37868–37876. [CrossRef]

46. Williamson, M.P. Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 2013, 73, 1–16. [CrossRef] [PubMed]

47. Bujak, E.; Matasci, M.; Neri, D.; Wulhfard, S. Reformattion of scFv Antibodies into the scFv-Fc Format and Their Downstream Purification. In Methods in Molecular Biology; Springer: New York, USA, 2014; Volume 1131, pp. 315–334. ISBN 9781627039918.

48. Ornitz, D.M.; Xu, J.; Colvin, J.S.; MacArthur, C.A.; Coulier, F.; Gao, G.; Goldfarb, M. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 1996, 271, 15292–15297. [CrossRef] [PubMed]

49. Zakrzewska, M.; Krowarsch, D.; Wiedlocha, A.; Otlewski, J. Design of fully active FGF-1 variants with increased stability. Protein Eng. Des. Sel. 2004, 17, 603–611. [CrossRef] [PubMed]

50. Zakrzewska, M.; Krowarsch, D.; Wiedlocha, A.; Olsnes, S.; Otlewski, J. Highly Stable Mutants of Human Fibroblast Growth Factor-1 Exhibit Prolonged Biological Action. J. Mol. Biol. 2005, 352, 860–875. [CrossRef]

51. Swiderska, K.W.; Szlachcic, A.; Czyrek, A.; Zakrzewska, M.; Otlewski, J. Site-specific conjugation of fibroblast growth factor 2 (FGF2) based on incorporation of alkyne-reactive unnatural amino acid. Bioorg. Med. Chem. 2017, 25, 3685–3693. [CrossRef] [PubMed]

52. Sokolowska-Wedzina, A.; Borek, A.; Chudzian, J.; Jakimowicz, P.; Zakrzewska, M.; Otlewski, J. Efficient production and purification of extracellular domain of human FGFR-Fc fusion proteins from Chinese hamster ovary cells. Protein Expr. Purif. 2014, 99, 50–57. [CrossRef] [PubMed]

53. Viti, F.; Nilsson, F.; Demartis, S.; Huber, A.; Neri, D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol. 2000, 326, 480–505. [CrossRef] [PubMed]

54. Sokolowska-Wedzina, A.; Chodaczek, G.; Chudzian, J.; Borek, A.; Zakrzewska, M.; Otlewski, J. High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer. Mol. Cancer Res. 2017, 15, 1040–1051. [CrossRef] [PubMed]

55. Schanda, P.; Brutscher, B. Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. J. Am. Chem. Soc. 2005, 127, 8014–8015. [CrossRef]

56. Flores-Flores, C.; Nissim, A.; Shochat, S.; Soreq, H. Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. J. Neural Transm. Suppl. 2002, 65–179.

57. Nissim, A.; Hoogenboom, H.R.; Tomlinson, I.M.; Flynn, G.; Midgley, C.; Lane, D.; Winter, G. Antibody fragments from a “single pot” phage display library as immunochemical reagents. EMBO J. 1994, 13, 692–698. [PubMed]